Innovate BC has announced $300,000 in funding through the Ignite program for TRIUMF and ARTMS to further develop and validate the production of zirconium-89 (Zr-89) for use in PET imaging scans for cancer patients eligible for immuno-oncology (IO) therapies.
A new paper published by TRIUMF Theory Department scientist Jason Holt and colleagues from the University of Washington and Germany has provided first-principles predictions of which isotopes can and can’t exist for elements from helium to iron.
On December 30th, 2020, Her Excellency the Right Honourable Julie Payette, Governor General of Canada announced 114 new appointments to the Order of Canada, including the recognition of two distinguished individuals from TRIUMF's Board of Management community.
TRIUMF scientists and engineers achieved a major milestone for the Advanced Rare Isotope Laboratory (ARIEL), maneuvering for the first time a radioactive isotope beam through ARIEL's CANREB facility and into the ISAC-II experimental hall.
Health Canada has approved cyclotron-produced technetium-99m, greenlighting the made-in-Canada technologyfor national implementation and opening the door toagreener, more reliableway to make the most commonly used medical isotope.
TRIUMF has announced a new research partnership with Ontario-based Fusion Pharmaceuticals to expand production and availability of actinium-225, a valuable but scarce radioisotope with tremendous promise as a cancer treatment.
